Business
Posting of Annual Report & Notice of AGM
Fusion Antibodies PLC announced that its Annual Report and Accounts for the year ended March 31, 2025, is being posted to shareholders. The Notice of the Company's Annual General Meeting (AGM) is also being distributed. The AGM will occur on Thursday, October 16, 2025, at 11:00 a.m. at the company's Belfast offices. The Notice of AGM and proxy form will be available for download on the company website. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nPosting of Annual Report & Notice of AGM\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Annual Report and Accounts for the year ended 31 March 2025 and the Notice of the Company's Annual General Meeting (\"AGM\") is being posted to shareholders today.\n \nThe Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here: https://www.fusionantibodies-ir.com/.\n \nThe AGM will be held on Thursday, 16 October 2025 at 11.00 a.m. at the offices of Fusion Antibodies plc, 1 Springbank Road, Springbank Industrial Estate, Belfast BT17 0QL.\n \nEnquiries: \n \n\n\n\n\nInvestor questions on this announcement\n\n\n\n\n\n\n\nWe encourage all investors to share questions on this announcement via our investor hub\n\n\nInvestor hub\n\n\n\n\n \n\n\n\n\n\n\n\nFusion Antibodies plc\n\n\nwww.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n \n\n\n\n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0) 20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\n\n\n\n\n\nDamon Heath (Joint Broker)\n\n\nTel: +44 (0) 207 186 9952\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: +44 (0)7876 741 001\n\n\n\n\n\n\n\n\n\n \nAbout Fusion Antibodies plc\n \nFusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.\n \nThe Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation u...